Rituxan (rituximab) is not effective at treating moderate to severe systemic lupus erythematosus (SLE) patients without kidney involvement, a new analysis of the Phase 2/3 trial EXPLORER concluded. The results confirm a prior analysis…
News
The Lupus Research Alliance has awarded grants of up to $600,000 each to seven scientists from across the U.S. to promote the development of innovative therapies for lupus, the organization announced. The initiative…
Abnormalities in the skeletal muscle are not a major contributor to the fatigue experienced by systemic lupus erythematosus (SLE) patients, a study based on magnetic resonance imaging (MRI) suggests, contradicting prior beliefs. The study, “Metabolic and structural skeletal muscle health in systemic lupus erythematosus related fatigue:…
Vaccinated patients with highly active systemic lupus erythematosus seem to lose their immunity levels over time, a study in rubella-vaccinated adolescents suggests. The study, “Risk factors associated with accelerated rubella-IgG antibody loss in previously vaccinated, treatment-naïve juvenile Systemic Lupus Erythematosus patients: a prospective study,” was published in the…
Stress, depression, and pain — but not disease activity, sleep, or physical health — appear to be major contributors to fatigue among patients with systemic lupus erythematosus (SLE), a new study reports. The findings support that screening and treatment of these measures are included in the usual care of SLE patients, particularly…
Omalizumab — a treatment already approved for allergic asthma and chronic hives — is well-tolerated and reduces disease activity in patients with systemic lupus erythematosus (SLE), a Phase 1b clinical trial shows. Findings were published in the study, “Safety and Tolerability of Omalizumab, A Randomized Clinical…
Neovacs and Centurion Pharma will continue the joint development of the investigational vaccine IFNalpha Kinoid for people with systemic lupus erythematosus (SLE) based on the positive results of a Phase 2b clinical study. The two companies had signed a licensing agreement in July 2017, establishing a…
A diet that is higher in fiber might benefit people with autoimmune diseases like lupus by reducing the amount of disease-causing bacteria in the gut, a new study suggests. The study, “A Diet-Sensitive Commensal Lactobacillus Strain, Mediates TLR7-Dependent Systemic Autoimmunity,” was published in Cell Host & Microbe.
Rituxan (rituximab), a medicine that is often used to treat systemic lupus erythematosus (SLE), may also be effective at treating skin lesions in patients with cutaneous lupus erythematosus (CLE), a study suggests. Researchers found that one year after treatment, 61% of patients experienced improvements in their skin lesions,…
High levels of a protein called HER2 in the urine can help identify children and adolescents with lupus who are at risk of serious kidney complications, a study suggests. While the study is still ongoing, the finding suggests that the use of approved HER2 inhibitors such as Tyverb (lapatinib)…
Recent Posts
- Noninvasive markers track lupus disease activity, kidney damage
- With lupus, I reframe my work life around small, creative endeavors
- I’m creating a personal curriculum specifically tailored to life with lupus
- Caught without my helpful spend-a-night bag
- AMETHYST trial of litifilimab making “strong progress,” Biogen says